Countdown 1 Day! 'Where Is Spring?' 2023 China Pharmaceutical Industry New Year Outlook Conference Starts Tomorrow at 9 AM!

Jan 10, 2023 13:00 CST Updated 13:00

微信图片_20230110201046.jpg

“Organized by E-Drug Manager and Wei Jie Yao,”2023 China Pharmaceutical Industry New Year Outlook Conference” will be held online on Wednesday, January 11, 2023. The Wei Jie Yao app will exclusively present all the highlights of the conference.

The China Pharmaceutical Industry New Year Outlook Conference, one of the flagship events hosted by E-Pharma Manager, has been held annually for six consecutive sessions since 2018.

For China’s pharmaceutical industry, winter arrived long ago, yet spring still seems distant. Just a year ago, fueled by the COVID-19 pandemic, capital flooded in, ushering in a period of prosperity and vibrant growth for the sector. However, with sudden shifts in policy, market dynamics, and the external environment, rationality has returned, and a “capital winter” has descended abruptly. Pharmaceutical companies, hunkering down, are either fortifying their resources or joining forces to weather the storm, striving with all their might simply to “survive.”

At the end of 2022, capital markets rose slightly as the external environment improved. Was this a warm winter sun or the breath of spring? With major adjustments to epidemic prevention policies, did this bring joy or concern to the pharmaceutical industry, which had invested heavily in the COVID-19 field? How can investor confidence and valuation logic, frozen by harsh headwinds, be rebuilt? How can patient-centric and clinical value-driven R&D be reshaped? Amid uncertainty, where lies the certain direction for the development of the pharmaceutical industry?

Against this backdrop, we have named the theme of this conference “Where Is Spring?”, we have invited numerous opinion leaders in the pharmaceutical industry to forecast 2023 from the perspectives of the macro-industrial environment, innovation and investment trends, marketing transformation, digitalization, and talent innovation, with the aim of clarifying uncertainties and accurately gauging the pulse of industrial development.

Guide to Watching This Conference Online

微信图片_20230110201051.png

“Scan the QR code to watch”

微信图片_20230110201055.png

“Scan the QR code to join the discussion group”

2023

What You Can Look Forward To

Stay Tuned

Highlight 1

9:00-9:40

[Macro Trends] New Opportunities for the Development of the Pharmaceutical and Healthcare Industry After the 20th National Congress of the Communist Party of China

What is the underlying logic behind the goals set for building a “Healthy China” over the next five years in the report to the 20th National Congress of the Communist Party of China? What new opportunities will emerge in the healthcare and pharmaceutical sectors?
Can the pharmaceutical economy quickly bottom out and rebound following the shift in national epidemic prevention and control policies?

Highlight 2

9:40-10:20

[Secondary Market] 2023The Evolution of Investment Logic in the Pharmaceutical Industry

2023Can the Market Performance of Pharmaceutical Stocks Reverse? Which sectors offer new investment opportunities after the market bottom is established?
Can Innovative Drug Companies Regain Investor Confidence in the Secondary Market? When Will They Break Through the Profitability Bottleneck?

Highlight 3

10:20-11:00

[Primary Market] 2023Outlook on Investment Strategies for Innovative Drugs

How can investor confidence and valuation logic, frozen by headwinds in innovative drug investment, be rebuilt? How will changes in the secondary market affect the primary market?
2023Which innovative sectors attracted the most capital attention this year?
Collaborative Landscape Between Industrial Capital and Investment Institutions.

Highlight 4

11:00-11:40

[R&D Innovation] Outlook on Global and China Biopharmaceutical R&D Innovation Trends in 2023

Core Trends in Global and Chinese Biopharmaceutical Innovation, 2023
2023 Outlook for Blockbuster and Disruptive Drug R&D Globally and in China
2023 Outlook for COVID-19 Vaccines and Therapies

Highlight 5

15:50-16:30

[Innovative Talents]Embracing Talent, Navigating the Winter: 2023 Pharmaceutical Talent Market Insights

The Current State of R&D Talent in the Innovative Drug Sector: When Will the Shortage Be Alleviated?
“When Will ‘Made-in-China’ Innovative Drug Talent Emerge?”

Highlight 6

16:30-17:10

[Active Pharmaceutical Ingredients] Strong Growth in Pharmaceutical Trade Imports and Exports / Analysis of China’s Dominant API Heparin Industry Chain and Centralized Procurement

The Global Pandemic Tests China’s API Industry: A Post-Pandemic Look at the International API Market
From the Part to the Whole: An Analysis of Guangdong’s Centralized Procurement and the Heparin Industry Chain in the Context of China’s 2023 National Centralized Procurement

Highlight 7

14:10-15:10

【High-End Dialogue】New Trends in Business Development for Innovative Drugs in China

What trend-driven shifts will business development (BD) at Chinese pharmaceutical companies undergo in the post-pandemic era? What impact did the two major cross-border licensing deals at the end of 2022 have on the overall ecosystem?
What Are the Differences in Business Development (BD) Capabilities Between Chinese and Overseas Pharmaceutical Companies?
How will BD consider the relevant technology protection systems in the United States and other developed countries in the future?

Meeting Agenda

微信图片_20230110201109.png

2022 Past Edition Review

Planned by E-Drug Manager and Wei Jie Yao“Survival” 2022 China Pharmaceutical Industry New Year Outlook Conference, with over 20,000 attendees,To watch the playback, please scan the QR code below.。

微信图片_20230110201117.jpg